BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34931674)

  • 21. [Oral nucleos(t)ide analogues antiviral therapy reduces HBV-related HCC: consensus and contention].
    Han C; Dou XG
    Zhonghua Gan Zang Bing Za Zhi; 2021 Apr; 29(4):293-296. PubMed ID: 33979951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence of hepatocellular carcinoma in chronic hepatitis B virus infection in those not meeting criteria for antiviral therapy.
    Alshuwaykh O; Daugherty T; Cheung A; Goel A; Dhanasekaran R; Ghaziani TT; Ahmed A; Dronamraju D; Kumari R; Kwong A; Nguyen M; Kim WR; Kwo PY
    Hepatol Commun; 2022 Nov; 6(11):3052-3061. PubMed ID: 36004713
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors associated with the biphasic kinetics of serum HBV RNA in patients with HBeAg-positive chronic hepatitis B treated with nucleos(t)ide analogues.
    Liu S; Liu Z; Li W; Zhou B; Liang X; Fan R; Deng R; Hou J; Sun J
    Aliment Pharmacol Ther; 2020 Aug; 52(4):692-700. PubMed ID: 32613672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis.
    Wang X; Liu X; Dang Z; Yu L; Jiang Y; Wang X; Yan Z
    Gut Liver; 2020 Mar; 14(2):232-247. PubMed ID: 31158948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
    Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Nucleos(t)ide Analogs on Patients with Intermediate and Advanced Hepatitis B Virus-Related Hepatocellular Carcinoma.
    Jian ZW; Wu XW; Chen ZX; Wang JC; Peng JY; Lao XM
    Dig Dis Sci; 2019 Aug; 64(8):2187-2198. PubMed ID: 30815819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
    Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
    Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients.
    Kim GA; Han S; Choi GH; Choi J; Lim YS
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1169-1179. PubMed ID: 32291781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy.
    Cheung KS; Seto WK; Wong DK; Lai CL; Yuen MF
    J Viral Hepat; 2017 Aug; 24(8):654-661. PubMed ID: 28185363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Liver histological status and clinic outcome in HBeAg-negative chronic hepatitis B with low viral load].
    Deng DL; Jiang JN; Su MH; Wang RM; Zang WW; Ling XZ; Wei HL; Liang XS; Zhou HK; He WM; Guo RS
    Zhonghua Gan Zang Bing Za Zhi; 2020 Dec; 28(12):1013-1017. PubMed ID: 34865348
    [No Abstract]   [Full Text] [Related]  

  • 31. Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B: Results of a 10-year follow up.
    Zhang W; Wang X; Wang Y; Zhao X; Duan W; Wang Q; Wu X; Kong Y; Ma H; You H; Ou X; Jia J
    Medicine (Baltimore); 2017 Nov; 96(44):e8454. PubMed ID: 29095292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma.
    Honda M; Shirasaki T; Terashima T; Kawaguchi K; Nakamura M; Oishi N; Wang X; Shimakami T; Okada H; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S
    J Infect Dis; 2016 Apr; 213(7):1096-106. PubMed ID: 26621908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score.
    Kaneko S; Kurosaki M; Joko K; Marusawa H; Kondo M; Kojima Y; Uchida Y; Kimura H; Tsuji K; Yagisawa H; Kusakabe A; Kobashi H; Akahane T; Tamaki N; Kirino S; Abe T; Yoshida H; Matsushita T; Hasebe C; Izumi N
    Sci Rep; 2020 Aug; 10(1):13021. PubMed ID: 32747646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease.
    Cho JY; Paik YH; Sohn W; Cho HC; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Gut; 2014 Dec; 63(12):1943-50. PubMed ID: 24615378
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues.
    Hosaka T; Suzuki F; Kobayashi M; Fujiyama S; Kawamura Y; Sezaki H; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    Aliment Pharmacol Ther; 2019 Feb; 49(4):457-471. PubMed ID: 30663078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic.
    Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Tanaka J
    J Gastroenterol Hepatol; 2017 Feb; 32(2):451-458. PubMed ID: 27288655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of antiviral therapy on post-hepatectomy outcome for hepatitis B-related hepatocellular carcinoma.
    Chong CC; Wong GL; Lai PB
    World J Gastroenterol; 2014 May; 20(20):6006-12. PubMed ID: 24876723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effect of interferon or nucleos(t)ide analogs on hepatitis B-related hepatocellular carcinoma].
    Liu ZH; Sun J
    Zhonghua Gan Zang Bing Za Zhi; 2019 Nov; 27(11):842-845. PubMed ID: 31941239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B.
    Kawaguchi K; Honda M; Ohta H; Terashima T; Shimakami T; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Komura T; Unoura M; Kaneko S
    J Gastroenterol; 2018 Jun; 53(6):740-751. PubMed ID: 28849280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The development of hepatocarcinoma after long-term antivirus treatment of Chinese patients with chronic hepatitis B virus infection: Incidence, long-term outcomes and predictive factors.
    Li ZQ; Hu CL; Yu P; Gu XY; Zhang JJ; Li H; Zhang HY; Lv J; Liu YM; Zeng QL; Yan JY; Yu ZJ; Zhang Y
    Clin Res Hepatol Gastroenterol; 2017 Jun; 41(3):311-318. PubMed ID: 28237828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.